Call for Abstract
Scientific Program
6th World Congress on Advanced Clinical Trials and Clinical Research, will be organized around the theme “Integrating precision in methodology, design and analysis of advanced clinical trials”
Clinical Trials Congress 2019 is comprised of keynote and speakers sessions on latest cutting edge research designed to offer comprehensive global discussions that address current issues in Clinical Trials Congress 2019
Submit your abstract to any of the mentioned tracks.
Register now for the conference by choosing an appropriate package suitable to you.
- Track 1-1Clinical research in academic level
- Track 1-2Trends & perspectives in clinical research
- Track 1-3Preclinical research considerations
- Track 1-4Informed consent for trials
- Track 1-5Real world clinical trial strategies and results
- Track 1-6Pharm a’s role in Bridging clinical research and health care
- Track 1-7Pharm a’s role in Bridging clinical research and health care
- Track 1-8Community outreach and education in clinical trials
- Track 1-9Business development tactics for clinical research sites
- Track 2-1Clinical research phase studies
- Track 2-2Challenges in conducting medical device trial
- Track 2-3Good clinical practice and inspection readiness
- Track 2-4Preparing data for FDA submission
- Track 2-5Emerging breakthroughs
- Track 2-6Misconduct and fraud in clinical trials
- Track 2-7Risks and benefits of participants
- Track 2-8Patient recruiting & retention
- Track 2-9Types of clinical trials
- Track 2-10Design of Clinical Studies and Trials
- Track 3-1SAS programming in data analysis
- Track 3-2Big data for clinical trials
- Track 3-3Statistical analysis methods
- Track 3-4On-shore & off-shore clinical data management
- Track 3-5Data integration and visualization
- Track 3-6Advanced products in data management
- Track 3-7Case report form (CRF/ECRF) design and development
- Track 3-8Data visualization & analytics techniques for clinical trial insights
- Track 3-9Clinical data management system validation
- Track 4-1Nutrigenomics
- Track 4-2Toxicogenomics
- Track 4-3Cancer pharmacogenomics
- Track 4-4Translational pharmacogenomics
- Track 4-5Challenges to pharmacogenomics
- Track 4-6Biomarker translation and testing
- Track 4-7Molecular-targeted interventions including gene therapy
- Track 5-1Molecular epidemiology
- Track 5-2Pharmacogenetics and biomarkers
- Track 5-3Clinical molecular genetics
- Track 5-4Clinical forensic medicine.
- Track 5-5Patterns of drug utilization
- Track 5-6The effect of drug overdoses.
- Track 5-7The economic implications of drug use.
- Track 5-8Discovery undetected adverse and beneficial effects
- Track 5-9Reassurance about drug safety
- Track 6-1Creating truly patient centric trials
- Track 6-2Patient centric approaches to clinical trials
- Track 6-3Patient perspective on research and health care
- Track 6-4Patient recruiting & retention
- Track 6-5Driving innovation in patient recruitment
- Track 6-6Innovative approaches to patient recruitment and retention
- Track 6-7Patient engagement and patient centricity
- Track 6-8Creating truly patient centric trials
- Track 6-9Creating patient centric trials using disruptive approaches to overcome barriers
- Track 7-1Priorities and needs of PV at different stages of a product life-cycle
- Track 7-2Challenges and opportunities in PV lifecycle management
- Track 7-3Safety surveillance and risk management lifecycle
- Track 7-4Innovations and trends in clinical drug safety
- Track 7-5REMS/RMP design,
- Track 7-6Post-marketing safety monitoring
- Track 7-7Pharmacovigillance in Drug Regulation
- Track 8-1Clinical Bioinformatics
- Track 8-2Software tools in clinical research
- Track 8-3Use of Databases in clinical trials
- Track 9-1Medical post market surveillance
- Track 9-2Report all the adverse drug reactions
- Track 9-3Better analytical tool and methods
- Track 9-4Controlled clinical trails
- Track 10-1Trails on digestive system and respiratory system
- Track 10-2Trials on cardiovascular disease
- Track 10-3Trials on behaviors mental, eating and sleeping disorder
- Track 10-4Studies on parasitic, viral, bacterial and fungal diseases
- Track 10-5Clinical trials on rare diseases
- Track 10-6Clinical trials for small sponsors
- Track 11-1Basis for a successful sponsor-cro partnership
- Track 11-2Better communications between sponsors, cros and sites
- Track 11-3Clinical trials for small sponsors
- Track 11-4Evolving strategic partnerships
- Track 11-5Develop the patient-pharma relationship in clinical research
- Track 11-6Globalization & Outsourcing
- Track 12-1Random screening
- Track 12-2Molecular manipulation
- Track 12-3Molecular designing
- Track 12-4Drug metabolites
- Track 12-5Serendipity
- Track 12-6High throughtput screening
- Track 12-7SAR studies
- Track 12-8In silicon screening
- Track 12-9Chemical synthesis
- Track 13-1Innovative approaches to patient recruitment
- Track 13-2Clinical trial site of the future
- Track 13-3Cloud based medical image management for clinical trials
- Track 13-4The good, the bad and the ugly of clinical trials
- Track 13-5Designing the clinical trial of the future
- Track 13-6Embracing the clinical trial of the future
- Track 13-7Global needs for mobile health and potential technologies
- Track 13-8Implementation of mobile health technologies
- Track 13-9Collaborate with patients to boost trial productivity
- Track 13-10Mobile technologies in clinical research
- Track 13-11Innovation in clinical technologies
- Track 13-12Strategic development towards FDA approval
- Track 13-13Innovative partnering in clinical research
- Track 13-14Paperless clinical trials
- Track 14-1Cancer and HIV/AIDS case reports
- Track 14-2Diabetes case reports
- Track 14-3Breast cancer case reports
- Track 14-4Dermatology, gastroenterology, Nephrology, pulmonology and urology case reports
- Track 14-5Case reports in neurology, ophthalmology, obstetrics and gynecology
- Track 15-1Trends in the globalization of clinical trials
- Track 15-2Strategies for successful globalization of clinical trials
- Track 15-3USA Clinical Trials
- Track 15-4Europe Clinical Trials
- Track 15-5UK Clinical Trials
- Track 15-6Japan Clinical Trials
- Track 15-7Asia Clinical Trials
- Track 16-1Optimization of medical device development
- Track 16-2Integrated framework from data to treatment
- Track 16-3Modeling for dose selection, special populations, drug interactions
- Track 16-4Collaborative cloud platform
- Track 16-5Trusted Partnership
- Track 16-6In-silico pre-clinical trials for implantable materials
- Track 16-7In silico study of drug behavior
- Track 17-1Strategic and tactical clinical outsourcing
- Track 17-2Fundamentals of outsourcing in clinical devices
- Track 17-3Strategic or tactical outsourcing
- Track 17-4Globalization & outsourcing
- Track 17-5Lean outsourcing models for clinical trials
- Track 17-6Generic drug repurposing clinical trials